Inventor · disambiguated record
Aaron P. Yamniuk
Also filed as: YAMNIUK AARON · YAMNIUK AARON P · YAMNIUK AARON PAUL
40 granted patents·21 pending applications·252 citations·filing 2012–2024
98Inventor score
Files withBRISTOL MYERS SQUIBB CO56UNIV ROCKEFELLER2ABCELLERA BIOLOGICS INC1BRISTOL MAYERS SQUIBB COMPANY1SURI ANISH1
Top patents by PatentIndex Score
61 records- 0197US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0296US11926673B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Mar 12, 2024·4 cites·18 claims
- 0396US11613585B2Nucleic acids encoding antagonistic CD40 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 28, 2023·3 cites·17 claims
- 0496US11254750B2Antagonistic CD40 monoclonal antibodies and uses in treating immune responsesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 22, 2022·6 cites·25 claims
- 0596US11220550B2Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activityBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 11, 2022·12 cites·15 claims
- 0696US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0796US8853154B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 7, 2014·35 cites·15 claims
- 0895US11008395B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Granted May 18, 2021·5 cites·25 claims
- 0994US12419953B2Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2024·Granted Sep 23, 2025·1 cites·20 claims
- 1094US11795231B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 24, 2023·2 cites·23 claims
- 1194US11773178B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 3, 2023·2 cites·17 claims
- 1294US8895010B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Nov 25, 2014·24 cites·36 claims
- 1393US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 1493US9493546B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 15, 2016·14 cites·20 claims
- 1591US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 1691US9475879B2Antibody polypeptides that antagonize CD40SURI ANISH·Filed 2012·Granted Oct 25, 2016·31 cites·15 claims
- 1791US9228018B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 5, 2016·11 cites·35 claims
- 1890US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 1988US11919954B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·1 cites·28 claims
- 2088US9765150B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 19, 2017·5 cites·37 claims
- 2188US8981072B2Nucleic acids encoding antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Mar 17, 2015·8 cites·27 claims
- 2287US10479838B2Antibodies to CD40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2016·Granted Nov 19, 2019·7 cites·10 claims
- 2387US2024316161A1Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2486US12409223B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Sep 9, 2025·0 cites·18 claims
- 2585US11261258B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 1, 2022·2 cites·14 claims
- 2684US11155618B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 26, 2021·1 cites·35 claims
- 2784US2024336695A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2881US2024228615A1Anti-trem-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2980US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3078US11306149B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 3178US10245302B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 2, 2019·1 cites·17 claims
- 3278US10196451B2Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40LBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 5, 2019·1 cites·20 claims
- 3378US2022073636A1Antibody polypeptides that antagonize cd40lBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3478US2024417478A1Antibodies against il-7r alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3577US11813315B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 14, 2023·0 cites·20 claims
- 3677US2023322941A1Antagonistic CD40 Monoclonal Antibodies and Uses ThereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3776US10787498B2Fibronectin type III domain proteins with enhanced solubilityBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 29, 2020·1 cites·3 claims
- 3874US11952427B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Apr 9, 2024·0 cites·20 claims
- 3974US11952420B2Nucleic acids encoding anti-TREM-1 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Apr 9, 2024·0 cites·25 claims
- 4074US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 4173US10544228B2Nucleic acids encoding antibody polypeptides that antagonize CD40BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 28, 2020·1 cites·17 claims
- 4272US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 4371US11919962B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·29 claims
- 4471US11180567B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 23, 2021·0 cites·20 claims
- 4571US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 4670US11512124B2Fibronectin type III domain proteins with enhanced solubilityBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Nov 29, 2022·0 cites·10 claims
- 4768US2021054091A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4867US10844130B2Nucleic acids encoding an anti-CD40 antibodyBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 24, 2020·0 cites·16 claims
- 4964US11136406B2Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40BRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 5, 2021·0 cites·20 claims
- 5064US2019055320A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Aaron P. Yamniuk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →